LPL Financial
GTBP icon

LPL Financial’s GT Biopharma GTBP Stock Holding History

LPL Financial’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Buy
36,379
+5,997
+20% +$2.43K ﹤0.01% 6137
2026
Q1 		$12.4K Buy
30,382
+19,750
+186% +$10.8K ﹤0.01% 5912
2025
Q4 		$8.35K Buy
+10,632
New +$7.55K ﹤0.01% 5854
2024
Q1 		– Sell
-1,144
Closed -$8.75K – 4967
2023
Q4 		$8.75K Buy
+1,144
New +$8.36K ﹤0.01% 4763

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

LPL Financial's GTBP Position: Q2 2026 in Review

LPL Financial increased its GT Biopharma (GTBP) stake by 20% in Q2 2026, buying an estimated $2.43K and bringing the position to 36,379 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6137.

LPL Financial first reported a position in GTBP in Q4 2023 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • LPL Financial held 36,379 shares of GT Biopharma worth $17.8K as of Q2 2026.
  • LPL Financial bought 5,997 GT Biopharma shares in Q2 2026, an estimated $2.43K.
  • GT Biopharma made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #6137 holding.
  • LPL Financial first reported a position in GT Biopharma in Q4 2023 and has held it in 4 quarters since.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.